Charleville Mezieres

Researchers are evaluating the effects of early intravenous high-dose vitamin C combined with vitamin B1 in patients admitted to intensive care after an out-of-hospital cardiac arrest (OHCA) who develop post-cardiac arrest shock. This shock involves heart and blood circulation failure and can lead to multiple organ failure and early death in up to 35% of patients. The study is a phase II multicenter randomized controlled trial designed to assess if vitamin C and vitamin B1 can improve outcomes compared to standard care following OHCA. Participants are randomly assigned to one of two groups. The experimental group receives standard care plus intravenous high-dose vitamin C at 200 mg/kg per day, given as 50 mg/kg every 6 hours for 3 days, starting within one hour after randomization. They also receive intravenous thiamine (vitamin B1) 200 mg twice daily for 3 days. The control group receives standard care according to guidelines, with no high-dose vitamin C during the first 3 days. From day 4, standard vitamin C and thiamine supplementation at lower doses are allowed. During the 28-day participation, patients are monitored for recovery from the shock, including the need for blood pressure support medications (vasopressors). The primary outcome is the cumulative rate of weaning off vasopressors by day 3 after cardiac arrest. Researchers will also assess safety and recovery progress. The study plans to enroll 234 patients over 24 months, with follow-up lasting 28 days after enrollment.

Researchers are evaluating whether giving amiodarone for 72 hours can reduce the risk of death or severe dangerous heart rhythms in critically ill patients admitted after an out-of-hospital cardiac arrest with a shockable heart rhythm and a confirmed or suspected cardiac cause. This phase 3 study focuses on improving outcomes within 30 days after treatment starts, addressing a critical period following cardiac arrest where complications are common. Participants receive an initial 300 mg loading dose of amiodarone over 30 minutes in a glucose solution, followed by a continuous infusion for 72 hours at a dose of 10 mg/kg per day, not exceeding 900 mg in 24 hours. The treatment is given through a central venous catheter in the intensive care unit. The study compares this preventive approach to standard care to see if it lowers the chance of death or severe ventricular arrhythmias requiring urgent intervention. During the study, participants are closely monitored in the ICU with regular assessments to track heart rhythms and overall health status. Researchers measure the rate of mortality and severe ventricular arrhythmias within 30 days from the start of treatment. Safety and treatment effects are carefully observed during this critical period to determine if prophylactic amiodarone can improve patient outcomes after cardiac arrest.